Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Migraine is a debilitating neurological condition affecting millions globally.
• Acute treatment options aim to rapidly relieve headache and associated symptoms.

Purpose of the Study:

• To evaluate the efficacy of rizatriptan 10 mg compared to placebo and rizatriptan 5 mg for acute migraine treatment.
• To assess sustained pain relief and symptom elimination over 24 hours.

Main Methods:

• Analysis of seven randomized, placebo-controlled, double-blind phase III clinical trials.
• Inclusion of 2068 patients treated with rizatriptan 10 mg, 1260 with placebo, and 1486 with rizatriptan 5 mg.
• Assessment of headache severity, associated symptoms, functional disability, and recurrence at various time points.

Main Results:

• Rizatriptan 10 mg demonstrated significantly higher pain relief (71% vs. 38%) and symptom elimination compared to placebo at 2 hours (P < 0.001).
• Sustained pain relief over 24 hours was significantly greater with rizatriptan 10 mg (37%) versus placebo (18%) (P < 0.001).
• Rizatriptan 10 mg showed significant superiority over rizatriptan 5 mg on most measures at 2 hours and for sustained pain relief over 24 hours (38% vs. 32%, P = 0.001).

Conclusions:

• Rizatriptan 10 mg is a highly effective treatment for the acute management of migraine attacks.
• The 10 mg dose offers superior efficacy and sustained relief compared to both placebo and the 5 mg dose.
• Rizatriptan 10 mg effectively alleviates headache, associated symptoms, and functional disability in migraine patients.